trial

A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

NCTId NCT05402111
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 31 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2023-09-27
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
31 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
None
Start
2022-06-13
Primary completion
2023-09-27
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
UlotarontAripiprazole

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Sites

7 total
Little Rock, United StatesRogers, United StatesLong Beach, United StatesSan Diego, United StatesHialeah, United StatesOakland Park, United StatesRichardson, United States

Facts & assertions

4 sourced
Enrollment
31
Phase
PHASE1
Primary Completion Date
2023-09-27
Status
COMPLETED
relationships
The graph out of here
drug
Ulotaront
drug
Aripiprazole
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication